CD4 and glioblastoma: Similarly, targeting GITR in a glioblastoma model using an agonistic antibody promoted CD4 Treg differentiation into CD4 Teffs, alleviated Treg-mediated suppression of anti-tumor immune response, and induced potent anti-tumor effector cells (147).